Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022

Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Persistence Market Research
Anti-Obesity Drugs Market - PMR Market
Insight Report 2016 to 2022
Persistence Market Research
1
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Persistence Market Research Released New Market Report on “Anti-Obesity Drugs
Market - PMR Market Insight Report 2016 to 2022”.
According to World Health Organization (WHO), obesity refers a disorder of
accumulation of excessive fat that can impair health. Body Mass Index (BMI) is an
index of weight for height, which is a measure for classifying obesity and
overweight. According to WHO, BMI greater than or equal to 30 is consider as an
Obese. Anti-obesity drugs refers the drugs that reduces or control the body weight
by either reducing the appetite or increasing the absorption of calories. The
fundamental treatment for obesity is to control over unhealthy diet, and regular
exercise, as although anti-obesity drugs are available in the market, their usefulness
is restricted to maintain weight rather than cure. Obesity is a risk factor for
development of several chronic diseases such as coronary heart diseases,
hypertension, metabolic disorders such as diabetes, and others. Hence, need to
control by proper medication, diet, and exercise. Bariatric surgery is an also option
for weight loss for BMI more than 40. However, lifelong changes in eating and
exercise habits are necessary after surgery.
Global anti-obesity drugs market segmented by approved drugs: buproprion and
naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and
topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global anti-obesity
drugs market segmented into North America, Europe, Asia Pacific, Latin America,
and rest of the World. Presently, North America holds largest share of the market
due to increasing obese population. For instance, according to Centers for Disease
Control and Prevention (CDC), more than one third of U.S. population is obese in
2014. However, Asia Pacific expected to grow at highest rate due to increasing
demand of drugs, and awareness regarding risk associated with obesity.
Additionally, sedentary lifestyle, and unhealthy diet would expect to increase the
number of obese people during forecast period.
Persistence Market Research
2
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Increase in incidence of obesity is majorly due to lack of physical activity, lack of
sleep, and high calorie diet. Additionally, family history, and consumption of certain
medicines such as antidepressant, diabetes agent also play a major role in obesity.
For instance, according to World Health Organization (WHO), about 13% of world’s
population were obese in 2014. Additionally, according to WHO, in emerging
countries the rate of increase of childhood obesity has been more than 30% higher
than that of developed countries. However, several side effects such as risk of
psychiatric disorder, non-fatal myocardial infraction, or stroke could affect the
market negatively albeit. Hence, development of medicines with lesser side effects
with chronic use, and increasing focus on developing countries market can help to
boost the market.
Interested in report: Please follow the below links to meet your requirements;
Request for the Report Brochure:
http://www.persistencemarketresearch.com/samples/8884
Request TOC (table of content), Figures and Tables of the Report:
http://www.persistencemarketresearch.com/toc/8884
Recently, in September 2014 U.S. FDA approved Contrave, an extended release
tablet for chronic weight management. Contrave is a combination of two already
FDA-approved drugs, naltrexone and bupropion, and distributed by Takeda
Pharmaceuticals America Inc. However, the drug is acting by very different
mechanism of mesolimbic pathway. Hence, approval of such a drugs in the market
could expect to surge the market growth.
For more Info: http://www.persistencemarketresearch.com/contact-us.asp
Key players in the global anti-obesity market are Arena Pharmaceuticals, BristolMyers Squibb, Alizyme, Boehringer Ingelheim GmbH, Eisai Company, Ltd., F.
Persistence Market Research
3
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Hoffmann-La Roche, GlaxoSmithKline plc, Bayer AG, Inc., Novo Nordisk, and Norgine
Pharmaceuticals Ltd. Additionally, some other company includes Orexigen
Therapeutics, Pfizer, Inc., Takeda Pharmaceutical, Rhythm Pharmaceuticals,
Shionogi USA, Vivus, Inc., and Zafgen.
About Us:
Persistence Market Research (PMR) is a
full-service market intelligence firm
specializing in syndicated research, custom research, and consulting services. PMR
boasts market research expertise across the Healthcare, Chemicals and Materials,
Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and
Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of
analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business
decisions. From ready-to-purchase market research reports to customized research
solutions, PMR’s engagement models are highly flexible without compromising on
its deep-seated research values.
Contact Us:
Persistence Market Research
305 Broadway,
7th Floor,
New York City, NY 10007,
United States.
Phone: +1-646-568-7751
USA/Canada Toll Free Number.
1-800-961-0353
E-mail: [email protected]
Web : http://www.persistencemarketresearch.com
Persistence Market Research
4